Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

Perspectives of clinicians and screening candidates on shared decision-making in prostate cancer screening with the prostate-specific antigen (PSA) test: a qualitative study (PROSHADE study)

  • Sanchis, María Jose
  • Guilabert, Mercedes
  • Parker, Lucy Anne
  • Caballero-Romeu, Juan-Pablo
  • Chilet Rosell, Elisa
  • Gómez-Pérez, Luis
  • Alonso Coello, Pablo
  • Cebrián-Cuenca, Ana
  • López Garrigós, Maite
  • Moral-Peláez, Irene
  • Ronda-Pérez, Elena
  • Canelo-Aybar, Carlos
  • Hernández Aguado, Ildefonso
  • Párraga-Martínez, Ignacio
  • Campo-Giménez, María del
  • Lumbreras, Blanca
  • Ronda-Pérez, Elena|||/items/d1e2ec4a-2b5f-4bb7-8ffa-54a8756606e0
Objective The objective of this study is to analyse the perspectives of screening candidates and healthcare professionals on shared decision-making (SDM) in prostate cancer (PCa) screening using the prostate-specific antigen (PSA) test. Design Descriptive qualitative study (May–December 2022): six face-to-face focus groups and four semistructured interviews were conducted, transcribed verbatim and thematically analysed using ATLAS.ti software. Setting Data were obtained as part of the project PROSHADE (Decision Aid for Promoting Shared Decision Making in Opportunistic Screening for Prostate Cancer) to develop a tool for SDM in PCa screening with PSA testing in Spain. Participants A total of 27 screening candidates (three groups of men: 40–50 years old; 51–60 years old and 61–80 years old), 25 primary care professionals (one group of eight nurses and two groups of physicians: one with more and one with less than 10 years of experience), and four urologists. Focus groups for patients and healthcare professionals were conducted separately. Main outcome measures Participants' perceptions of shared decision-making related to PSA opportunistic screening, including their understanding, preferences, and attitudes. Results Three themes were generated: (1) perceptions of SDM, (2) perceptions of PSA testing and (3) perceptions of SDM regarding PCa screening. Theme 1: screening candidates valued SDM when it included clear information and empowered them. There was consensus with primary care health professionals on this point, although their knowledge and implementation of SDM varied. Theme 2: candidates were divided on PSA testing; some trusted it for early detection, while others expressed scepticism due to concerns about false positives and invasive procedures, reflecting gaps in accessible information. Theme 3: professionals across primary and specialised care stressed the need for standardised SDM protocols. Primary care physicians were particularly concerned that PSA decisions align with scientific evidence and urologists recognised SDM as valuable in PSA testing only if it was adequately explained to each patient. Barriers to implementing SDM included insufficient coordination across care levels, lack of consensus-driven protocols and limited clinical time. Conclusions While patients expect comprehensive information, primarily based on practice to achieve empowerment, healthcare professionals face obstacles such as limited time and insufficient coordination between primary care and urology. All stakeholders agree on the importance of evidence-based tools to reinforce effective SDM and enhance collaboration across urologists and primary care in the context of PSA testing.
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

Disparities in prostate cancer screening practices among general practitioners and urologists (PROSHADE study): A cross-sectional study

  • Lumbreras, Blanca
  • Parker, Lucy Anne
  • Alonso Coello, Pablo
  • Caballero-Romeu, Juan-Pablo
  • Párraga-Martínez, Ignacio
  • Prieto, Luis
  • Moral-Peláez, Irene
  • Campo-Giménez, María del
  • Gómez-Pérez, Luis
  • Cebrián-Cuenca, Ana
  • López Garrigós, Maite
  • Ronda-Pérez, Elena
  • Guilabert, Mercedes
  • Canelo-Aybar, Carlos
  • Hernández Aguado, Ildefonso
  • Ronda-Pérez, Elena|||/items/d1e2ec4a-2b5f-4bb7-8ffa-54a8756606e0
Introduction: Recent European recommendations promote risk-based, patient-centred screening models that emphasise shared decision-making (SDM) in prostate cancer (PCa) screening with prostate-specific antigen (PSA) testing. Understanding how clinicians apply these practices is essential, particularly given the roles of general practitioners (GPs) and urologists in detection. The aim of this study was to compare the knowledge, attitudes, and practices of GPs and urologists in Spain regarding PSA testing, PCa screening, and SDM implementation. Methods: Cross-sectional survey conducted via an online questionnaire. Members of the Spanish Association of Urology (AEU) and the Spanish Society of Family and Community Medicine (semFYC) were surveyed online. The survey, developed and validated using a modified Delphi process, contained 18 items assessing clinicians’ opinions, practices, and knowledge of guidelines. Data from 494 respondents (280 GPs and 214 urologists) were analysed using descriptive statistics and logistic regression to explore differences between specialty, demographics, and screening practices. Results: Urologists were more likely than GPs to consider PSA testing important (97.2% vs. 83.2%) and useful (96% vs. 44.4%), and to recommend it to relatives (90.4% vs. 44%) (all p < 0.001). They reported to initiate testing earlier (50–59 years: 77.8% vs. 32%) and reported to perform it more frequently (annual testing: 60.7% vs. 45.6%, p < 0.001). GPs reported to more often engaged in SDM when ordering PSA tests (69.7% vs. 10%, p < 0.001). Knowledge of guidelines was higher among urologists (91% vs. 24.1%), yet 75.4% stated that they had not modified practice following updated recommendations. Conclusions: Significant specialty-based differences exist in PSA testing practices, perceptions, and guideline adherence. Urologists show greater familiarity with recommendations, while GPs reported more patient-centred communication.
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

Impact of patients’ age and comorbidities on prostate cancer overdiagnosis in clinical practice

  • Beltrán, Abraham
  • Parker, Lucy Anne
  • Moral-Peláez, Irene
  • Caballero-Romeu, Juan-Pablo
  • Chilet Rosell, Elisa
  • Hernández Aguado, Ildefonso
  • Alonso Coello, Pablo
  • Ronda-Pérez, Elena
  • Gómez-Pérez, Luis
  • Lumbreras, Blanca
  • Ronda-Pérez, Elena|||/items/d1e2ec4a-2b5f-4bb7-8ffa-54a8756606e0
Introduction. Overdiagnosis in PSA-based prostate cancer (PCa) screening is primarily studied in younger, healthier populations from clinical trials. This study aimed to evaluate the probability of overdiagnosis in PCa screening within a clinical practice context, focusing on its relationship with PSA levels, Gleason scores, and subsequent clinical procedures. Methods. We conducted a retrospective cohort analysis of 1,070 asymptomatic men over 40 years old diagnosed with PCa between 2004 and 2022, following a positive PSA test. The patients were followed until December 31, 2022, with a median follow-up time of 5.7 years (IQR 3.2–8.6). The primary outcome was the probability of overdiagnosis, assessed through life expectancy and the Charlson Comorbidity Index, considering lead times of 5, 10, and 15 years. Results. We found that patients with PSA levels >10 ng/dL and/or Gleason scores ≥8 were generally older and had more comorbidities than those with PSA levels 4–10 ng/dL and/or Gleason scores ≤7. The probability of overdiagnosis was significantly higher in patients with PSA levels >10 ng/dL (41.4%, IQR 21.5–73.9) and Gleason scores ≥8 (42.6%, IQR 14.9–38.9), compared to those with PSA levels 4–10 ng/dL (20.1%, IQR 12.8–30.4) and Gleason scores ≤7 (26.6%, IQR 23.6–68.6). Notably, 71.7% of patients did not receive pharmacological treatment. Patients with higher PSA levels also experienced greater radiation exposure from diagnostic imaging (median 19.9 mSv vs. 14.7 mSv, p = 0.004). Conclusions. These findings underscore the high likelihood of overdiagnosis in older patients with elevated PSA levels and significant comorbidities, highlighting the need for careful consideration of patient comorbidities before PSA testing.
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

PROSHADE Protocol: Designing and Evaluating a Decision Aid for Promoting Shared Decision Making in Opportunistic Screening for Prostate Cancer: A Mix-Method Study

  • Lumbreras, Blanca
  • Parker, Lucy Anne
  • Alonso Coello, Pablo
  • Mira-Bernabeu, Javier
  • Gómez-Pérez, Luis
  • Caballero-Romeu, Juan-Pablo
  • Pertusa-Martínez, Salvador
  • Cebrián-Cuenca, Ana
  • Moral-Peláez, Irene
  • López Garrigós, Maite
  • Canelo-Aybar, Carlos
  • Ronda-Pérez, Elena
  • Guilabert, Mercedes
  • Prieto-González, Antonio
  • Hernández Aguado, Ildefonso
  • Ronda-Pérez, Elena|||/items/d1e2ec4a-2b5f-4bb7-8ffa-54a8756606e0
Background: Opportunistic prostate-specific antigen (PSA) screening may reduce prostate cancer mortality risk but is associated with false positive results, biopsy complications and overdiagnosis. Although different organisations have emphasised the importance of shared decision making (SDM) to assist men in deciding whether to undergo prostate cancer screening, recent evaluations show that the available decision aids fail to facilitate SDM, mainly because they do not consider the patients’ perspective in their design. We aim to systematically develop and test a patient decision aid to promote SDM in prostate cancer screening, following the Knowledge to Action framework. Methods: (1) Feasibility study: a quantitative survey evaluating the population and clinician (urologists and general practitioners) knowledge of the benefits and risks derived from PSA determination and the awareness of the available recommendations. Focus groups to explore the challenges patients and clinicians face when discussing prostate cancer screening, the relevance of a decision aid and how best to integrate it into practice. (2) Patient decision aid development: Based on this data, an evidence-based multicomponent SDM patient decision aid will be developed. (3) User-testing: an assessment of the prototype of the initial patient decision aid through a user-testing design based on mix-methods (questionnaire and semi-structured review). The decision aid will be refined through several iterative cycles of feedback and redesign. (4) Validation: an evaluation of the patient decision aid through a cluster-randomised controlled trial. Discussion: The designed patient decision aid will provide balanced information on screening benefits and risks and should help patients to consider their personal preferences and to take a more active role in decision making. Conclusions: The well-designed patient decision aid (PDA) will provide balanced information on screening benefits and risks and help patients consider their personal preferences.
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

Knowledge and practices regarding prostate cancer screening in Spanish men: The importance of personal and clinical characteristics (PROSHADE study)

  • Parker, Lucy Anne
  • Caballero-Romeu, Juan-Pablo
  • Chilet Rosell, Elisa
  • Hernández Aguado, Ildefonso
  • Gómez-Pérez, Luis
  • Alonso Coello, Pablo
  • Cebrián-Cuenca, Ana
  • López Garrigós, Maite
  • Moral-Peláez, Irene
  • Ronda-Pérez, Elena
  • Gilabert, Mercedes
  • Canelo-Aybar, Carlos
  • Párraga-Martínez, Ignacio
  • Campo-Giménez, María del
  • Lumbreras, Blanca
  • Ronda-Pérez, Elena|||/items/d1e2ec4a-2b5f-4bb7-8ffa-54a8756606e0
Introduction Patients’ decisions on prostate cancer (PCa) opportunistic screening may vary. This study aimed to assess how demographic and health-related characteristics may influence knowledge and decisions regarding PCa screening. Methods A cross-sectional survey was conducted among men aged over 40, randomly sampled from the Spanish population, 2022. The survey underwent development and content validation using a modified Delphi method and was administered via telephone. Binomial logistic regression was used to explore the relationship between respondents’ characteristics and participants’ knowledge and practices concerning PCa and the PSA test. Results Out of 1,334 men, 1,067 (80%) respondents were interviewed with a mean age of 58.6 years (sd 11.9). Most had secondary or university studies (787, 73.8%) and 61 (5.7%) self-reported their health status as bad or very bad. Most of the respondents (1,018, 95.4%) had knowledge regarding PCa with nearly 70% expressed significant concern about its potential development (720, 70.8%), particularly among those under 64 years (p = 0.001). Out of 847 respondents, 573 (67.7%) reported that they have knowledge regarding the PSA test: 374 (65.4%) reported receiving information from a clinicians, 324 (86.6%) information about the benefits of the test and 189 (49,5%) about its risks, with differences based on educational background. In a multivariable analysis (adjusted for age, educational level and previous prostate problems), respondents with higher levels of education were more likely to have higher knowledge regarding the PSA test (OR 1.75, 95%CI 1.24–2.50, p<0.001). Conclusions Although most of the patients reported to have knowledge regarding PCa, half of the interviewed men reported knowledge about PSA test. Differences in knowledge prostate cancer screening and undesirable consequences highlight the need to develop and provide tailored information for patients.
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

Barriers and facilitators of shared decision-making in prostate cancer screening in primary care: A systematic review

  • Estevan-Vilar, María
  • Parker, Lucy Anne
  • Caballero-Romeu, Juan-Pablo
  • Ronda-Pérez, Elena
  • Hernández Aguado, Ildefonso
  • Lumbreras, Blanca
  • Ronda-Pérez, Elena|||/items/d1e2ec4a-2b5f-4bb7-8ffa-54a8756606e0
Objective: To identify barriers and facilitators of the implementation of shared decision-making (SDM) on PSA testing in primary care. Design: Systematic review of articles. Data sources: PubMed, Scopus, Embase and Web of Science. Eligibility criteria: Original studies published in English or Spanish that assessed the barriers to and facilitators of SDM before PSA testing in primary care were included. No time restrictions were applied. Data extraction and synthesis: Two review authors screened the titles, abstracts and full texts for inclusion, and assessed the quality of the included studies. A thematic synthesis of the results were performed and developed a framework. Quality assessment of the studies was based on three checklists: STROBE for quantitative cross-sectional studies, GUIDED for intervention studies and SRQR for qualitative studies. Results: The search returned 431 articles, of which we included 13: five cross-sectional studies, two intervention studies, five qualitative studies and one mixed methods study. The identified barriers included lack of time (healthcare professionals), lack of knowledge (healthcare professionals and patients), and preestablished beliefs (patients). The identified facilitators included decision-making training for professionals, education for patients and healthcare professionals, and dissemination of information. Conclusions: SDM implementation in primary care seems to be a recent field. Many of the barriers identified are modifiable, and the facilitators can be leveraged to strengthen the implementation of SDM.